Clinicopathologic Significance of Putative Stem Cell Marker, CD44 and CD133, in Human Gastric Carcinoma
Background and Objectives CD44 and CD133 have been reported as putative stem cell markers. However, the clinicopathologic significance of CD44 and CD133 expression in patients with gastric carcinoma (GC) has not been clearly elucidated. Methods Immunohistochemistry (IHC) was performed to investigate...
Saved in:
Published in | Journal of surgical oncology Vol. 107; no. 8; pp. 799 - 806 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken
Wiley Subscription Services, Inc., A Wiley Company
01.06.2013
Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Background and Objectives
CD44 and CD133 have been reported as putative stem cell markers. However, the clinicopathologic significance of CD44 and CD133 expression in patients with gastric carcinoma (GC) has not been clearly elucidated.
Methods
Immunohistochemistry (IHC) was performed to investigate the CD44 and CD133 expression in gastric carcinomas and normal mucosal tissues. Receiver operating characteristic (ROC) curve analysis, spearman's rank correlation, Kaplan–Meier plots, and Cox proportional hazards regression model were used to analyze the data.
Results
The highly expressed CD44 and CD133 were observed in 27/152 (17.7%) and 64/152 (42.1%) of GCs and in 4/60 (6.7%) and 15/60 (25.0%) normal gastric mucosal tissues, respectively (P < 0.05, Fisher's exact test). High expression of CD44 was significantly correlated with tumor poorer differentiation, presence of distant metastasis, advanced TNM stage, and tumor relapse; and high expression of CD133 was positively associated with tumor invasion depth, presence of distant metastasis and advanced TNM stage. More importantly, high‐expressed CD44 and CD133 were both associated with shorter survival as evidenced by univariate and multivariate analysis.
Conclusions
Our study introduces high expression of CD44 and CD133 as adverse independent prognostic factors in GC patients. The combined CD44 and CD133 expression may become a useful tool for identifying patients with different clinical outcomes. J. Surg. Oncol. 2013;107:799–806. © 2013 Wiley Periodicals, Inc. |
---|---|
Bibliography: | Ying-Bo Chen and Mu-Yan Cai contributed equally to this work. Conflict of interest statement: None declared. istex:3DD1586DB1A9DB4754669342F7816DC30EF8CA0C ark:/67375/WNG-XVR9WK9D-5 ArticleID:JSO23337 Ying‐Bo Chen and Mu‐Yan Cai contributed equally to this work. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ISSN: | 0022-4790 1096-9098 1096-9098 |
DOI: | 10.1002/jso.23337 |